November 10-15

The official news source of

ACR Convergence 2023

San Diego, CA

Home // Daniel Wallace, MD: Efficacy and safety of evobrutinib in SLE

Daniel Wallace, MD: Efficacy and safety of evobrutinib in SLE


1 minute

Daniel Wallace, MD

Poster presenter: Daniel Wallace, MD, professor of medicine, David Geffen School of Medicine at UCLA, associate director of the Rheumatology Fellowship Program, Cedars-Sinai Medical Center.

Poster title: Efficacy and Safety of Evobrutinib (M2951) in Adult Patients with Systemic Lupus Erythematosus Who Received Standard of Care Therapy: A Phase II, Randomized, Double-blind, Placebo-controlled Dose Ranging Study

Scheduled poster session: Saturday, Nov. 7, 9 – 11 a.m. EST

Visit the Poster Hall

What is your poster about?

Bruton’s tyrosine kinase (BTK) is involved in signaling pathways known to be important to the pathogenesis of systemic lupus erythematosus (SLE). Evobrutinib is a highly selective oral BTK inhibitor. This global Phase IIb, randomized, double-blind, placebo-controlled study evaluated the efficacy, dose response, and safety of evobrutinib compared with placebo in adult patients with active autoantibody-positive SLE who received standard of care therapy. The study randomized 469 patients.

What are you working on next related to this poster?

The study demonstrated safety but no therapeutic effect, and there were no safety concerns. This is consistent with other BTK inhibitors studies for rheumatoid arthritis and SLE. Future work in this area for SLE is unlikely.